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Context:Kallmannsyndrome(KS), combinedpituitaryhormonedeficiency (CPHD), andsepto-optic
dysplasia (SOD)all result fromdevelopmentdefectsof theanteriormidline in thehumanforebrain.
Objective: The objective of the study was to investigate whether KS, CPHD, and SOD have shared
genetic origins.
Design and Participants: A total of 103 patients with either CPHD (n  35) or SOD (n  68) were
investigatedformutations ingenes implicated intheetiologyofKS(FGFR1,FGF8,PROKR2,PROK2, and
KAL1). Consequences of identified FGFR1, FGF8, and PROKR2mutations were investigated in vitro.
Results: Three patients with SOD had heterozygous mutations in FGFR1; these were either shown
to alter receptor signaling (p.S450F, p.P483S) or predicted to affect splicing (c.336CT, p.T112T).
One patient had a synonymous change in FGF8 (c.216GA, p.T72T) that was shown to affect
splicingand ligand signalingactivity. FourpatientswithCPHD/SODwere foundtoharborheterozy-
gous rare loss-of-function variants in PROKR2 (p.R85G, p.R85H, p.R268C).
Conclusions: Mutations in FGFR1/FGF8/PROKR2 contributed to 7.8% of our patients with CPHD/
SOD. These data suggest a significant genetic overlap between conditions affecting the develop-
ment of anterior midline in the human forebrain. (J Clin Endocrinol Metab 97: E694–E699, 2012)
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In the vertebrate embryo, the preplacodal field arises atthe edge of the neural plate adjacent to the neural crest,
and its derivatives give rise to neuronal and nonneuronal
head structures (1). Cells within the preplacodal field sep-
arate into individual placodes, of which the most anterior
are the adenohypophyseal, lens, and olfactory placodes
(1). The adenohypophyseal placode gives rise to the in-
termediate and anterior pituitary lobes (2). The olfactory
placode gives rise to different cell types, including vome-
ronasal neurons, support cells, mucous-producing cells,
and GnRH neurons (1). These developmental processes
are orchestrated by multiple transcription factors and sig-
naling molecules (2).
Mutations in the transcription factors SOX2, SOX3,
HESX1, and OTX2 have been implicated in septo-optic
dysplasia (SOD), a disorder characterized by pituitary
hormone deficiencies, optic nerve hypoplasia, andmidline
defects including agenesis of the septum pellucidum
and/or corpus callosum (3). Furthermore, mutations in
transcription factors PROP1, POU1F1, LHX3, and
LHX4 underlie combined pituitary hormone deficiency
(CPHD) (4). However, such mutations only account for a
small percentage of all CPHD/SOD cases.
A different set of genes have been implicated in Kall-
mann syndrome [KS; defined as idiopathic hypogonado-
tropic hypogonadism (IHH) and anosmia/hyposmia].
These genes, KAL1, PROK2, PROKR2, FGFR1, and
FGF8, play critical roles in the development of olfactory
system and GnRH neuron ontogeny (5). KS manifests as
absent or incomplete puberty, sexual immaturity, and in-
fertility, and additional phenotypes include midline de-
fects (5).
FGFR1 and FGF8 are expressed inRathke’s pouch and
in the ventral diencephalon, respectively (6), and murine
transcriptome data have identified members of the fibro-
blast growth factor (FGF)-8 signaling network during pi-
tuitary development (7). We therefore hypothesized that
mutations in genes underlying KS could also underlie
CPHD and/or SOD.
Subjects and Methods
Patients and control subjects
A total of 103 patients with either sporadic CPHD (n 35) or
sporadic SOD (n  68) were included. Patients were recruited at
four medical centers in the United States and the United Kingdom.
Patientswith SODexhibitedoptic nervehypoplasia, agenesis of the
corpus callosum, and/or septum pellucidum on radiologic exami-
nation with or without pituitary hormone deficiencies (4). CPHD
was diagnosed as a deficiency of at least two pituitary hormones.
Unaffected control subjects (n 268)were also studied. The ethics
committees of participating institutions approved the study, and
written informed consent was obtained before participation from
subjects/parents/guardians.
ThedescriptionofDNAsequencingofKAL1,FGFR1,FGF8,
PROK2, and PROKR2 and the assessment of the functional
consequences of FGF receptor (FGFR)-1, FGF8, and prokineti-
cin receptor 2 (PROKR2) mutations have been previously re-
ported. Detailed descriptions of these methods as well as a de-
scription of Prokr2 promoter reporter gene expression in the
mouse pituitary are provided in the Supplemental Data, pub-
lished on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org.
Results
Among 103 patients with either CPHD (n  35) or SOD
(n  68), four unrelated probands (3.9%) harbor rare
sequence variants in FGFR1 or FGF8, and four (3.9%)
have PROKR2 variants (Table 1). All mutations are
heterozygous, and, in most cases, DNA from the parents
was not available. The probands’ phenotypic data are de-
tailed in Table 1 and case descriptions are provided in the
Supplemental Data. Notably, a number of probands ex-
hibited a reproductive phenotype consistent with hypogo-
nadotropic hypogonadism based on their neonatal pre-
sentation because they are yet prepubertal.
FGFR1 and FGF8 mutations in patients with SOD
Three FGFR1 heterozygous mutations were identified
in SOD probands (Table 1). The FGFR1 variant
c.1349CT, p.S450Fmaps to the intracellular domain of
the receptor upstream of the tyrosine kinase domain and
the amino acid (S450) is highly conserved across verte-
brates (Supplemental Fig. 1A). The S450Fmutant FGFR1
exhibits total protein and receptor cell surface expression
levels (Fig. 1A and Supplemental Fig. 1B) similar to wild
type (WT), yet downstream signaling is severely compro-
mised (Fig. 1B). The FGFR1 variant c.1447CT p.P483S
maps to a highly conserved residue in the tyrosine kinase
domain. P483S also exhibits normal expression levels
(Fig. 1A)but disrupteddownstreamsignaling (Fig. 1B).Of
note, the affected amino acid residue is also mutated in a
patient with KS (c.1447CA, p.P483T, Pitteloud, N., un-
published data). Subject 1 harbors a synonymous change
(c.336CT, p.T112T) mapping to the C-terminal end of
immunoglobulin-like domain 1 (Supplemental Fig. 1A).
This changewas not observed in the 268 healthy controls,
in the single-nucleotide polymorphism database or in the
1000 genomes data set. The Human Splicing Finder soft-
ware (8) predicts that this variant generates a new exonic
splicing enhancer binding site (TTACTTC) for the SRp40
splicing factor [score 79.46 (0–100)] and/or disrupts an
overlapping putative exonic splicing enhancer octamer
(CCTACTTC) (score 31.53).
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A synonymous change in FGF8 (c.216GA p.T72T)
was identified in a CPHD proband. This variant (Supple-
mental Table 1) is predicted by theHuman Splicing Finder
program (8) to compromise an exonic splicing enhancer
site for the serine/arginine-rich splicing factor SF2/ASF
(9).We generated aminigene expression construct, which
includes the entire FGF8 gene (exons 1a to 3) except for
2.4 kb of intron 1d sequence (Supplemental Fig. 2), to
measure relative expression levels of the four FGF8 iso-
forms in transfected cells using quantitative RT-PCR.
Consistent with the software prediction, the e and f iso-
form transcripts (which incorporate an alternatively
spliced exon, 1c) expressed from the mutant construct
were significantly elevated compared with WT (Fig. 1C).
We further assessed the biological significance of themini-
gene-induced alterations in gene expression and found
that the mutant construct displayed significantly higher
activity in a luciferase transcription reporter assay com-
pared with WT (Fig. 1D).
PROKR2 and KAL1 mutations in patients with SOD
or CPHD
Three differentPROKR2mutationswere found in four
patients with SOD or CPHD. One Caucasian and one
African SOD proband both harbor the identical heterozy-
gous PROKR2 variant (c.802CT, p.R268C) (Table 1
and Supplemental Fig. 3A), previously reported in asso-
ciation with both normosmic IHH and KS (10, 11) and
shown to be loss of function in vitro (11). The other
PROKR2 variant (c.253CG, p.R85G) found in a SOD
proband affects an amino acid conserved across verte-
brates (Supplemental Fig. 3A) and is predicted to be loss of
function (Supplemental Table 1). Western analysis indi-
cates reduced total protein expression suggesting a defect
in protein folding and stability (Fig. 1E). Accordingly, cell
surface expression is significantly reduced (Fig. 1F) ac-
companied by a severe decrease in signaling via both cal-
cium (Fig. 1G) and MAPK (Supplemental Fig. 3B) (log
TABLE 1. Phenotypes of SOD and CPHD probands found to harbor gene mutations in either FGFR1, FGF8, or
PROKR2
Patient
SOD  hormone deficiencies CPHD
1 2 3 5 6 7 4 8
Rare variant FGFR1
T112T
FGFR1
S450F
FGFR1
P483S
PROKR2
R85G
PROKR2
R268C
PROKR2
R268C
FGF8
T72T
PROKR2
R85H
KAL1
H459Y
Gender Male Male Female Female Male Male Female Male
Abnormal pituitary MRI No No Yes No Yes Yes Yes N/A
Anterior pituitary Hypoplastic Hypoplastic
Posterior pituitary Undescended Ectopic Prominent
Infundibular stalk Agenesis
Hormone deficiencies Yes Yes Yes Yes Yes Yes Yes Yes
GH X X X X X X
TSH X X X X X
ACTH X X X
LH/FSH Xa Xa Xa Xa Xa Xa X Xa
AVP X
Midline defects Yes Yes Yes Yes Yes No No No
Corpus callosum Agenesis Agenesis Hypoplastic Hypoplastic
Septum pellucidum
Other 1 central incisor Cleft lip/palate Cleft lip/palate
schizencephaly
Ocular defects Yes No Yes Yes Yes Yes No No
Optic nerves Agenesis (L) Hypoplasia
Optic disc Hypoplasia Hypoplasia
Other Abnormal eyes Micropthalmia
coloboma
Reproductive phenotypes N/A N/A N/A N/A Yes Yes Yes Yes
Cyrptorchidism X X
Microphallus X X
Delayed puberty X
Other phenotypes Seizures ASD and VSD,
brachydactyly,
brachycephaly,
preauricular
skin tags
None Club foot, syrinx
spinal cord
Microcephaly,
epilepsy
None None None
MRI, Magnetic resonance imaging; AVP, arginine vasopressin; ASD, atrial septal defect; VSD, ventricular septal defect.
a Hypogonadotropic hypogonadism is based on neonatal diagnosis (phenotype: cryptorchidism/micorphallus or low serum gonadotropins or LHRH
stimulation test).
E696 Raivio et al. Genetic Overlap in KS, CPHD, and SOD J Clin Endocrinol Metab, April 2012, 97(4):E694–E699
EC50 WT 6.944  0.155, R85G
6.319  0.267, P  0.05) cascades.
A CPHD proband, born with a mi-
crophallus (suggesting neonatal GnRH
deficiency), harbors a rare variant in
KAL1 (c.1375CT), inherited fromhis
mother, and a mutation in PROKR2
(c.254GA, p.R85H) inherited from
his father. The R85H mutation has
been reported in KS patients (12) and is
loss of function in vitro (13). Trans-
genicmice expressing green fluorescent
staining (GFP) under control of the
Prok2 promoter shows GFP immuno-
reactivity throughout the pituitary
structures, and especially in the pars
nervosa (Fig. 1H), further supporting a
role for PROK2 signaling in the
pituitary.
Discussion
We describe eight prepubertal patients
with CPHD/SOD carrying a heterozy-
gous mutation in FGFR1, FGF8, or
PROKR2, associated with altered fu-
nction. Thus, mutations in genes gen-
erally associatedwith IHH/KSmayalso
be associated with CPHD/SOD, dem-
onstrating a genetic overlap between
these syndromes. Patients with KS of-
ten display midline defects such as cleft
lip and/or palate and corpus callosum
anomalies, and FGF8 mutations were
recently found to be associated with re-
cessive holoprosencephaly, craniofa-
cial defects, and hypothalamo-pitu-
itary dysfunction (6). Additionally, as
early as in 1954, deMorsier described a
syndrome of dysplasie olfacto-ge´nitale,
which included agenesis of the olfac-
tory bulbs, corpus callosum, and the
anterior commissure aswell as infantile
genitalia (14). Although the hypogo-
nadotropic hypogonadism observed in
both CPHD and SOD is thought to be
of pituitary origin, the verification of
hypothalamic GnRH deficiency in these
patients is difficult, if not impossible, be-
cause of the concomitant presence of a
pituitary defect.
FIG. 1. A, Western blotting analysis showing similar overall expression and maturation levels
of mutant FGFR1 compared with WT. FGFR1 was detected using an anti-myc antibody and
the blot was reprobed with heat-shock protein 90 to demonstrate equal loading. UT,
Untreated; PG, PNGase F treated; EH, endoglycosidase H treated; HSP90, heat-shock protein
90. B, Luciferase reporter assay using the osteocalcin FGF response elements reporter showing
decreased signaling activity by FGFR1 S450F and FGFR1 P483S. ***, P  0.001 at maximal
dose. C, Quantitative PCR showing that expression of both the FGF8e and FGF8f isoforms is
significantly increased compared with WT. ***, P  0.001; *, P  0.05). D, Representative
experiment of a transcriptional reporter (AP1-luciferase) assay of FGF8 WT and T72T mutant
minigene showing increased signaling activity by the mutant ligand compared with WT.
*, P  0.05 at maximal dose. E, Western analysis showing that overall expression of the
PROKR2 mutant (R85G) is reduced compared with WT. F, Expression of the PROKR2 R85G
mutant at the cell surface is significantly reduced compared with WT. *, P  0.05 in a
radiolabeled antibody binding assay. G, The PROKR2 R85G mutant receptor is loss of function
in the aequorin reporter assay. ***, P  0.001. H, Prokr2 is expressed in the adult mouse
pituitary. Immunofluorescent staining for GFP in the pituitary of Prokr2-GFP transgenic mice
shows immunoreactivity in all pituitary structures and is most pronounced in the pars nervosa.
AVP, Arginine vasopressin.
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As with the FGFR1mutations in IHH/KS patients, the
mutations identified in SOD probands are also loss of
function. In contrast, the FGF8 mutation in the CPHD
proband shows enhanced downstream receptor signaling.
The rare synonymous change in FGF8 leads to differential
expression of FGF8 isoforms and enhanced FGFR1 sig-
naling in vitro. Thus far, gain-of-function FGFR1 muta-
tions have been reported only in osteoglophonic dysplasia
and Pfeiffer syndrome. Of note, 40% of patients with Ap-
ert syndrome (caused by activating FGFR2 mutations)
havepartial or complete absenceof the septumpellucidum
and 23% have corpus callosum defects (15), phenotypes
also observed in SOD. Thus, it remains unclear whether
CPHD is caused by increased (and not decreased) FGF
signaling or, more broadly, by any significant perturba-
tion of FGF signaling.
There are some precedents of IHH/KS sharing the same
genetic basis with another developmental disorder. Mu-
tations in CHD7 occur in CHARGE syndrome
(coloboma, heart defect, choanal atresia, retardation, gen-
ital hypoplasia, ear anomalies) and KS patients (16). Sim-
ilarly, a frameshift mutation in SOX2 associated with
anophthalmia/microphthalmia was also found in an IHH
patient (17), suggesting that SODand IHH share a genetic
basis. Furthermore, deletion of Otx2, a locus for SOD,
targeted to GnRH neurons results in hypogonadotropic
hypogonadism in mice (18).
We also evaluated the PROK2/PROKR2 pathway in
patients with CPHD/SOD, identifying three loss-of-func-
tionmutations inPROKR2 in four unrelatedCPHD/SOD
probands. The PROKR2 R268C variant has been de-
scribed in heterozygous state in IHH/KS patients, healthy
first-degree relatives of KS probands, and in one of 250
healthy controls (10, 12).We therefore propose that these
mutations do not cause major midline defects per se, but
may act as modifier genes, or contribute to the phenotype
through digenic inheritance, as previously demonstrated
in IHH/KS (19, 20). Thus, further studies are needed to
elucidate the role of PROKR2 signaling in pituitary and
midline development. In conclusion, this report identified
substantial genetic overlap between syndromes affecting
the anterior midline and associated with the primitive
placode.
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